Vaxxinity announces publication of ub-311 safety, tolerability, immunogenicity, and clinical efficacy data from phase 2a trial in alzheimer's disease

Phase 2a data published in the lancet's ebiomedicine supports further development of ub-311 the paper concludes that ub-311 is the most advanced active immunotherapy targeting beta-amyloid in the clinic ub-311 could offer multiple competitive advantages over licensed passive immunotherapies, including  less frequent dosing, a more convenient mode of administration, improved accessibility and cost-effectiveness, and potentially lower rates of aria-e cape canaveral, fla., aug. 10, 2023 (globe newswire) -- vaxxinity, inc. (nasdaq: vaxx), a u.s. company pioneering the development of a new class of medicines, today announced the print publication of phase 2a clinical trial data in the lancet's ebiomedicine (volume 94, 104665, august 2023), stating that ub-311 “was safe and well-tolerated,” with early clinical data demonstrating a trend for slowing cognitive decline in mild alzheimer's disease (ad).
VAXX Ratings Summary
VAXX Quant Ranking